Literature DB >> 2974045

Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.

F Miedema1, A J Petit, F G Terpstra, J K Schattenkerk, F de Wolf, B J Al, M Roos, J M Lange, S A Danner, J Goudsmit.   

Abstract

To investigate the effect of persistent HIV infection on the immune system, we studied leukocyte functions in 14 asymptomatic homosexual men (CDC group II/III) who were at least two years seropositive, but who still had normal numbers of circulating CD4+ T cells. Compared with age-matched heterosexual men and HIV-negative homosexual men, the CD4+ and CD8+ T cells from seropositive men showed decreased proliferation to anti-CD3 monoclonal antibody and decreased CD4+ T-helper activity on PWM-driven differentiation of normal donor B cells. Monocytes of HIV-infected homosexual men showed decreased accessory function on normal T cell proliferation induced by CD3 monoclonal antibody. The most striking defect in leukocyte functional activities was observed in the B cells of HIV-infected men. B cells of 13 out of 14 seropositive men failed to produce Ig in response to PWM in the presence of adequate allogeneic T-helper activity. These findings suggest that HIV induces severe immunological abnormalities in T cells, B cells, and antigen-presenting cells early in infection before CD4+ T cell numbers start to decline. Impaired immunological function in subclinically HIV-infected patients may have clinical implications for vaccination strategies, in particular the use of live vaccines in groups with a high prevalence of HIV seropositivity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974045      PMCID: PMC442771          DOI: 10.1172/JCI113809

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

2.  Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.

Authors:  R Yarchoan; R R Redfield; S Broder
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

3.  B-cell immunodeficiency in acquired immune deficiency syndrome.

Authors:  A J Ammann; G Schiffman; D Abrams; P Volberding; J Ziegler; M Conant
Journal:  JAMA       Date:  1984-03-16       Impact factor: 56.272

4.  Immunoregulatory subsets of the T helper and T suppressor cell populations in homosexual men with chronic unexplained lymphadenopathy.

Authors:  J K Nicholson; J S McDougal; T J Spira; G D Cross; B M Jones; E L Reinherz
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells.

Authors:  W J Tax; H W Willems; P P Reekers; P J Capel; R A Koene
Journal:  Nature       Date:  1983 Aug 4-10       Impact factor: 49.962

6.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

9.  Immunoglobulin production in human mixed lymphocyte cultures: implications for co-cultures of cells from patients and healthy donors.

Authors:  H C Rümke; F G Terpstra; B Huis; T A Out; W P Zeijlemaker
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

10.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  110 in total

Review 1.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection.

Authors:  Enrique Espinosa; Christopher E Ormsby; Gustavo Reyes-Terán; Robert Asaad; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

3.  HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy.

Authors:  S Resino; I Galán; A Pérez; J A León; E Seoane; D Gurbindo; M Angeles Muñoz-Fernandez
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

4.  Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.

Authors:  Diana Edo-Matas; Philippe Lemey; Jennifer A Tom; Cèlia Serna-Bolea; Agnes E van den Blink; Angélique B van 't Wout; Hanneke Schuitemaker; Marc A Suchard
Journal:  Mol Biol Evol       Date:  2010-12-06       Impact factor: 16.240

5.  Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

Authors:  H Lim; L Kane; J B Schwartz; C S Hesdorffer; S G Deeks; N Greig; L Ferrucci; E J Goetzl
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

6.  Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression.

Authors:  A H Patki; M E Quiñones-Mateu; D Dorazio; B Yen-Lieberman; W H Boom; E K Thomas; M M Lederman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

7.  IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy.

Authors:  E Stylianou; P Aukrust; D Kvale; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

8.  Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals.

Authors:  M Paiardini; D Galati; B Cervasi; G Cannavo; L Galluzzi; M Montroni; D Guetard; M Magnani; G Piedimonte; G Silvestri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals.

Authors:  Y Sasaki; A Blanchard; H L Watson; S Garcia; A Dulioust; L Montagnier; M L Gougeon
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.

Authors:  Susan Moir; Kisani M Ogwaro; Angela Malaspina; Joshua Vasquez; Eileen T Donoghue; Claire W Hallahan; Shuying Liu; Linda A Ehler; Marie A Planta; Shyamasundaran Kottilil; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.